Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics (Nasdaq: GANX) reported 2025 year-end results and a clinical update for lead candidate GT-02287. Key metrics: net loss $20.2M (2025), cash and marketable securities $20.8M at 12/31/25, R&D $10.2M, G&A $8.5M. Clinical highlights include Phase 1b extension enrollment of 16 participants (14 completed Day 150), an average 81% decrease in CSF GluSph after 90 days in participants with elevated baseline, and IND interaction with FDA with IND clearance expected in 2Q26. Phase 2 is expected to begin in 3Q26 and Phase 1b results are expected in 4Q26.
Gain Therapeutics (NASDAQ: GANX) announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026. The fireside chat is scheduled for March 23, 2026 at 11:30 a.m. PT.
Investors can access a live webcast or replay via the company website or contact ir@gaintherapeutics.com to arrange meetings through ROTH representatives.
Gain Therapeutics (NASDAQ: GANX) presented Phase 1b clinical and preclinical data at AD/PD 2026 supporting continued development of GT-02287 and a new chemical series led by GT-04686.
Key clinical signals include reductions in CSF glucosylsphingosine (GluSph) after 90 days, decreased CSF DOPA decarboxylase (DDC) in high‑GluSph participants, and durable MDS‑UPDRS scores through Day 150. The novel series is ready for IND‑enabling studies; the Part 1 safety profile supported a nine‑month extension expected to complete in September 2026.
Gain Therapeutics (NASDAQ: GANX) will present Phase 1b interim data for GT-02287 at AD/PD 2026 on March 18, 2026 and at a poster session March 17-21, 2026 in Copenhagen. The company reported CNS target engagement, pathway biomarker effects and early clinical improvement signals.
Gain submitted an IND response to the U.S. FDA in March 2026 and expects a reply in the coming weeks; the company remains on track to start a placebo-controlled Phase 2 trial in 3Q 2026.
Gain Therapeutics (Nasdaq: GANX) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, including a fireside chat at 1:20 p.m. ET.
A replay will be made available via the company website and investors can request one-on-one meetings through Oppenheimer or by contacting ir@gaintherapeutics.com.
Gain Therapeutics (NASDAQ: GANX) announced its participation in events during the week of the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Jan 11–14, 2026.
Planned events include: the 9th Annual Sachs Neuroscience Innovation Forum on Jan 11, 2026 (presentation and one-on-ones; presentation at 2:40 p.m., Track C — Rosenberg Room, Marine's Memorial Club), the Demy-Colton/Informa Biotech Showcase on Jan 12–14, 2026 (presentation and one-on-ones; Hilton San Francisco Union Square), and the LifeSci Advisors 15th Annual Corporate Access Event on Jan 14, 2026 (one-on-one meetings; The Beacon Grand).
Investors can request in-person meetings via the Biotech Showcase partnering system or by registering/contacting LifeSci Advisors representative Alex Grossman (alex@lifesciadvisors.com).
Gain Therapeutics (Nasdaq: GANX) reported Phase 1b biomarker and clinical data for GT-02287 on January 6, 2026, showing biochemical and clinical signals after 90 days of dosing.
Key findings: in participants with elevated baseline cerebrospinal fluid glucosylsphingosine (GluSph), GluSph fell 81% on average after 90 days; as of Nov 30, 2025, 19 patients completed Part 1 (90 days), and 15 evaluable patients showed an average -2.20 point change in the sum of MDS‑UPDRS Part II+III (Part II: -0.6; Part III: -1.6). Four patients were excluded from MDS‑UPDRS analysis (two alpha-synuclein assay negative; two missing ‘off’ state scores). The company describes the GluSph reduction as a first-ever CSF observation after a GCase modulator and says results support continued development and evaluation in the dosing extension.
Gain Therapeutics (Nasdaq: GANX) will host a virtual key opinion leader event on January 6, 2026 at 10:00 a.m. EST titled “Understanding GCase Substrates in Parkinson’s Disease: Perspectives on Biomarkers and Disease Modification”.
Featured speakers include Roy Alcalay, M.D., M.Sc. and Peter Lansbury, Ph.D.. The program will review biomarker results from the Phase 1b clinical study of GT-02287, described as demonstrating disease‑modifying potential in Parkinson’s disease patients with or without a GBA1 mutation. A live question-and-answer session will follow the presentations and registration is required.
Gain Therapeutics (Nasdaq: GANX) announced Phase 1b data showing first-ever reduction of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) after 90 days of dosing with GT-02287, a GCase modulator for Parkinson’s disease. The prespecified exploratory endpoint suggests CNS target engagement and increased GCase activity. The 21-participant study had 19 completers; 15 (79%) entered a nine-month extension expected to finish in September 2026. GT-02287 was generally well tolerated and the DMC recommended continuation. A virtual KOL webinar is scheduled for Jan 6, 2026.
Gain Therapeutics (Nasdaq: GANX) presented preclinical data for lead candidate GT-02287 at Neuroscience 2025 (Nov 15–19, 2025) showing mitochondrial and neuronal benefits across three models.
Key findings: reduced mitochondrial ROS and prevented cytochrome C release in MPP+-treated rat dopaminergic neurons; reduced MIRO1 staining in an α-synuclein mouse PD model; and increased mitochondrial GCase, boosted complex I activity, and improved membrane potential in patient fibroblasts with the L444P GBA1 mutation. The company said these results support a mechanism of GCase trafficking to mitochondria and lysosomes and reinforce planned 90-day human biomarker analyses.